Amylyx's avexitide reduces hypoglycemic event rate by 55% in Phase 3 trial

• Amylyx Pharmaceuticals will present Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek 2026 on November 15.
• Avexitide significantly reduced hypoglycemic events versus placebo, meeting the primary endpoint and all prespecified secondary event-rate endpoints in patients following gastric bypass.
• Treatment was generally well tolerated, with mostly mild-to-moderate gastrointestinal and injection-site reactions; no treatment-related serious adverse events occurred.
• A U.S. marketing application is targeted by year-end, with a potential commercial launch in 2027 if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261114240218) on November 14, 2026, and is solely responsible for the information contained therein.